Biosimilar monoclonal antibodies (mAbs) to TNF are being developed that are highly similar, but not identical to the innovator molecules. CT-P13, a biosimilar of infliximab, is the first anti-TNF mAb to get approval in South Korea, Europe and Canada. However, uncertainties remain about indication extrapolation and interchangeability.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
Advances in Therapy Open Access 10 November 2021
-
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Pharmaceutical Research Open Access 31 May 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Park, W. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72, 1605–1612 (2013).
Yoo, D. H. et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 72, 1613–1620 (2013).
Ben-Horin, S. et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut http://dx.doi.org/10.1136/gutjnl-2015-309290.
Ravetch, J. V. & Bolland, S. IgG Fc receptors. Ann. Rev. Immunol. 19, 275–290 (2001).
Feagan, B. G. et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 42, 177–183 (2014).
Shen, C. et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21, 251–258 (2005).
Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774–1785 (2003).
Xu, Z. et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J. Clin. Pharmacol. 48, 681–695 (2008).
Fasanmade, A. A. et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 65, 1211–1228 (2009).
Kuo, T. T. et al. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 30, 777–789 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.V.C. is a Postdoctoral Fellow of the Research Foundation-Flanders (FWO), Belgium, received consultancy fees from Janssen Biologics BV, MSD, Pfizer and UCB, and speaker's fees from Abbvie. W.J.S. received research support and consultancy fees from Abbvie, Amgen, Janssen and Pfizer, and consultancy fees from UCB.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Vande Casteele, N., Sandborn, W. Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol 12, 373–374 (2015). https://doi.org/10.1038/nrgastro.2015.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.104
This article is cited by
-
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
Advances in Therapy (2022)
-
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Pharmaceutical Research (2020)
-
Biosimilars in IBD: from theory to practice
Nature Reviews Gastroenterology & Hepatology (2017)
